Title: Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents.
Journal: Advances in therapy 20121001
Title: Drug metabolite heterogeneity in cultured single cells profiled by pico-trapping direct mass spectrometry.
Journal: Nanomedicine (London, England) 20120901
Title: Comparison of efficacy of four prostaglandin analogues by bilateral treatment in healthy subjects.
Journal: Japanese journal of ophthalmology 20120701
Title: Efficacy and ocular surface tolerability of preservative-free tafluprost 0.0015%: a 6-month, single-blind, observational study on naïve ocular hypertension or glaucoma patients.
Journal: Expert opinion on drug safety 20120701
Title: Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension.
Journal: American journal of ophthalmology 20120601
Title: Spanish multicenter tafluprost tolerability study.
Journal: The British journal of ophthalmology 20120601
Title: Tafluprost (Zioptan) - a new topical prostaglandin for glaucoma.
Journal: The Medical letter on drugs and therapeutics 20120416
Title: In vitro study of antiadipogenic profile of latanoprost, travoprost, bimatoprost, and tafluprost in human orbital preadiopocytes.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20120401
Title: FDA approves glaucoma treatment.
Journal: American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20120315
Title: Ocular hypotensive effect of tafluprost in latanoprost low-responder cynomolgus monkeys.
Journal: Journal of glaucoma 20120201
Title: A prospective study evaluating IOP changes after switching from a therapy with prostaglandin eye drops containing preservatives to nonpreserved tafluprost in glaucoma patients.
Journal: TheScientificWorldJournal 20120101
Title: Clobazam, ezogabine, and tafluprost.
Journal: Journal of the American Pharmacists Association : JAPhA 20120101
Title: Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.
Journal: Japanese journal of ophthalmology 20111101
Title: Tafluprost for glaucoma.
Journal: Expert opinion on pharmacotherapy 20111001
Title: Tafluprost: a novel prostaglandin analog for treatment of glaucoma.
Journal: Advances in therapy 20110901
Title: Preservative-free tafluprost 0.0015% in the treatment of patients with glaucoma and ocular hypertension.
Journal: Advances in therapy 20110701
Title: Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system.
Journal: The British journal of ophthalmology 20110601
Title: Metabolism and ocular tissue distribution of an antiglaucoma prostanoid, tafluprost, after ocular instillation to monkeys.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20110601
Title: Effects of prostaglandin F(2α) analogues on endothelin-1-induced impairment of rabbit ocular blood flow: comparison among tafluprost, travoprost, and latanoprost.
Journal: Experimental eye research 20101201
Title: Effects of benzalkonium chloride-preserved, polyquad-preserved, and sofZia-preserved topical glaucoma medications on human ocular epithelial cells.
Journal: Advances in therapy 20101101
Title: Effects of topical phenylephrine and tafluprost on optic nerve head circulation in monkeys with unilateral experimental glaucoma.
Journal: Investigative ophthalmology & visual science 20100801
Title: IOP-lowering efficacy and tolerability of preservative-free tafluprost 0.0015% among patients with ocular hypertension or glaucoma.
Journal: Current medical research and opinion 20100801
Title: Twenty-four-hour ocular hypotensive effects of 0.0015% tafluprost and 0.005% latanoprost in healthy subjects.
Journal: Japanese journal of ophthalmology 20100701
Title: [Optimization of benzalkonium chloride concentration in 0.0015% tafluprost ophthalmic solution from the points of ocular surface safety and preservative efficacy].
Journal: Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20100601
Title: In vitro toxicity of topical ocular prostaglandin analogs and preservatives on corneal epithelial cells.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20100601
Title: A review of preserved and preservative-free prostaglandin analogues for the treatment of open-angle glaucoma and ocular hypertension.
Journal: Drugs of today (Barcelona, Spain : 1998) 20100601
Title: [Intraocular pressure lowering effect of 0.0015% tafluprost as compared to placebo in patients with normal tension glaucoma: randomized, double-blind, multicenter, phase III study].
Journal: Nippon Ganka Gakkai zasshi 20100501
Title: Switching from a preserved to a preservative-free prostaglandin preparation in topical glaucoma medication.
Journal: Acta ophthalmologica 20100501
Title: Effects of repeated administrations of tafluprost, latanoprost, and travoprost on optic nerve head blood flow in conscious normal rabbits.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20100401
Title: A phase II study on the duration and stability of the intraocular pressure-lowering effect and tolerability of Tafluprost compared with latanoprost.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20100201
Title: Efficacy and safety of tafluprost 0.0015% versus latanoprost 0.005% eye drops in open-angle glaucoma and ocular hypertension: 24-month results of a randomized, double-masked phase III study.
Journal: Acta ophthalmologica 20100201
Title: Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo.
Journal: Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 20091001
Title: Disposition and metabolism of a novel prostanoid antiglaucoma medication, tafluprost, following ocular administration to rats.
Journal: Drug metabolism and disposition: the biological fate of chemicals 20090801
Title: Corneal penetration into rabbit aqueous humor is comparable between preserved and preservative-free tafluprost.
Journal: Ophthalmic research 20090101
Title: Adjunctive use of tafluprost with timolol provides additive effects for reduction of intraocular pressure in patients with glaucoma.
Journal: European journal of ophthalmology 20090101
Title: [Receptors involved in the mechanism of action of topical prostaglandines].
Journal: Oftalmologia (Bucharest, Romania : 1990) 20090101
Title: Short-term effects of topical tafluprost on retinal blood flow in cats.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20081001
Title: Relaxing effect and mechanism of tafluprost on isolated rabbit ciliary arteries.
Journal: Experimental eye research 20080901
Title: Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride.
Journal: The British journal of ophthalmology 20080901
Title: Tafluprost, a new potent prostanoid receptor agonist: a dose-response study on pharmacodynamics and tolerability in healthy volunteers.
Journal: International journal of clinical pharmacology and therapeutics 20080801
Title: In vitro effects of preservative-free tafluprost and preserved latanoprost, travoprost, and bimatoprost in a conjunctival epithelial cell line.
Journal: Current eye research 20080401
Title: In search of improved prostaglandin treatment for glaucoma.
Journal: Acta ophthalmologica. Supplement 20080101
Title: Pharmacokinetics, efficacy and safety profiles of preserved and preservative-free tafluprost in healthy volunteers.
Journal: Acta ophthalmologica. Supplement 20080101
Title: Efficacy and safety levels of preserved and preservative-free tafluprost are equivalent in patients with glaucoma or ocular hypertension: results from a pharmacodynamics analysis.
Journal: Acta ophthalmologica. Supplement 20080101
Title: [Glaucoma--strategy of treatment].
Journal: Oftalmologia (Bucharest, Romania : 1990) 20080101
Title: A comparative, placebo-controlled study of prostanoid fluoroprostaglandin-receptor agonists tafluprost and latanoprost in healthy males.
Journal: Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20070801
Title: The IOP-lowering effects and mechanism of action of tafluprost in prostanoid receptor-deficient mice.
Journal: The British journal of ophthalmology 20070501
Title: Prostaglandin analogues and mouse intraocular pressure: effects of tafluprost, latanoprost, travoprost, and unoprostone, considering 24-hour variation.
Journal: Investigative ophthalmology & visual science 20050601
Title: Pharmacological characteristics of AFP-168 (tafluprost), a new prostanoid FP receptor agonist, as an ocular hypotensive drug.
Journal: Experimental eye research 20040401
Title: New fluoroprostaglandin F(2alpha) derivatives with prostanoid FP-receptor agonistic activity as potent ocular-hypotensive agents.
Journal: Biological & pharmaceutical bulletin 20031201
Title: Kuwayama, Y. and A. Nomura, Prospective observational post-marketing study of tafluprost for glaucoma and ocular hypertension: short-term efficacy and safety. Adv Ther, 2014. 31(4): p. 461-71.
Title: Kumagami, T., et al., Comparison of corneal safety and intraocular pressure-lowering effect of tafluprost ophthalmic solution with other prostaglandin ophthalmic solutions. J Ocul Pharmacol Ther, 2014. 30(4): p. 340-5.
Title: Inoue, K., A. Tanaka, and G. Tomita, Effects of tafluprost treatment for 3 years in patients with normal-tension glaucoma. Clin Ophthalmol, 2013. 7: p. 1411-6.
